is an Indicator of Prognosis in Breast Cancer Patients

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2015 Jul 15

PMID 26171207

Citations 25

Authors

Yoshiaki Shinden

Tomohiro Iguchi

Sayuri Akiyoshi

Hiroki Ueo

Masami Ueda

Hidenari Hirata

Shotaro Sakimura

Ryutaro Uchi

Yuki Takano

Hidetoshi Eguchi

Keishi Sugimachi

Yuko Kijima

Shoji Natsugoe

Koshi Mimori

Affiliations

Soon will be listed here.

Abstract

MicroRNA-29b () targets numerous important genes that mediate carcinogenesis and tumor development in breast cancer and . The aim of the present study was to determine the clinical significance of expression in primary breast cancer patients. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of and certain target genes of , such as DNA methyltransferase 3A (), ten-eleven translocation 1 () and thymine DNA glycosylase (), was performed in 94 primary breast cancer samples. Low expression of in primary tumors was significantly associated with poorer disease-free survival (DFS) (P=0.0075) and overall survival (OS) (p=0.0012). Multivariate analysis indicated that expression was an independent prognostic factor for OS [relative risk=15.6 (2.33-348), P=0.0026]. In addition, a significant inverse correlation was identified between the expression levels of and in estrogen receptor-positive breast cancer patients (P=0.027). To the best of our knowledge, this is the first study to investigate the clinicopathological significance of in breast cancer cases and is shown to act as a tumor suppressive microRNA in breast cancer and as a potential marker for recurrence and metastasis in breast cancer patients.

Citing Articles

Let-7b, miR-29b, and miR-125b as Potential Biomarkers for Differentiating Canine Mammary Carcinoma Histological Types.

Ferreira T, Dias F, Alves A, Gama A, Mano J, Oliveira P Animals (Basel). 2025; 15(1.

PMID: 39794962 PMC: 11718878. DOI: 10.3390/ani15010020.

Prediction of miRNA-disease associations based on PCA and cascade forest.

Zhang C, Li Y, Dong Y, Chen W, Yu C BMC Bioinformatics. 2024; 25(1):386.

PMID: 39701957 PMC: 11660965. DOI: 10.1186/s12859-024-05999-w.

Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer.

Abbas M, Sayed I, Kamel Abdu-Allah A, Kalam A, Al-Sehemi A, Al-Hartomy O Noncoding RNA Res. 2022; 7(4):248-257.

PMID: 36247409 PMC: 9530401. DOI: 10.1016/j.ncrna.2022.09.003.

Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches.

Grassilli S, Bertagnolo V, Brugnoli F Diagnostics (Basel). 2022; 12(9).

PMID: 36140539 PMC: 9497770. DOI: 10.3390/diagnostics12092139.

The Role of miR-29s in Human Cancers-An Update.

Nguyen T, Suman K, Nguyen T, Nguyen H, Do D Biomedicines. 2022; 10(9).

PMID: 36140219 PMC: 9495592. DOI: 10.3390/biomedicines10092121.

References

Meireles Da Costa N, Hautefeuille A, Cros M, Melendez M, Waters T, Swann P . Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle. 2012; 11(24):4570-8. PMC: 3562302. DOI: 10.4161/cc.22843. View

Goldhirsch A, Wood W, Senn H, Glick J, Gelber R . Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer. 1995; 31A(11):1754-9. DOI: 10.1016/0959-8049(95)00479-3. View

Lu H, Zhan W, Yan L, Qin R, Yan Y, Yang Z . TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol Med Rep. 2014; 10(5):2595-600. DOI: 10.3892/mmr.2014.2517. View

Cao X, Ma H, Shang Y, Jin M, Kong F, Jia Z . DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer. World J Gastroenterol. 2014; 20(25):8201-8. PMC: 4081693. DOI: 10.3748/wjg.v20.i25.8201. View

Ng E, Li R, Shin V, Siu J, Ma E, Kwong A . MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol. 2013; 35(3):2591-8. DOI: 10.1007/s13277-013-1341-7. View

Tejero R, Navarro A, Campayo M, Vinolas N, Marrades R, Cordeiro A . miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One. 2014; 9(7):e101899. PMC: 4087018. DOI: 10.1371/journal.pone.0101899. View

Niederwieser C, Kohlschmidt J, Volinia S, Whitman S, Metzeler K, Eisfeld A . Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2014; 29(3):567-75. PMC: 4351165. DOI: 10.1038/leu.2014.267. View

Starlard-Davenport A, Kutanzi K, Tryndyak V, Word B, Lyn-Cook B . Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach. J Carcinog. 2013; 12:15. PMC: 3746452. DOI: 10.4103/1477-3163.115720. View

Yang H, Yu J, Wang L, Ding D, Zhang L, Chu C . miR-320a is an independent prognostic biomarker for invasive breast cancer. Oncol Lett. 2014; 8(3):1043-1050. PMC: 4114662. DOI: 10.3892/ol.2014.2298. View

10.

Yu Z, Xiao Q, Zhao L, Ren J, Bai X, Sun M . DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. Mol Carcinog. 2014; 54(9):707-19. DOI: 10.1002/mc.22133. View

11.

Xu X, Yu T, Shi J, Chen X, Zhang W, Lin T . Thymine DNA glycosylase is a positive regulator of Wnt signaling in colorectal cancer. J Biol Chem. 2014; 289(13):8881-90. PMC: 3979391. DOI: 10.1074/jbc.M113.538835. View

12.

Sun M, Song C, Huang H, Frankenberger C, Sankarasharma D, Gomes S . HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A. 2013; 110(24):9920-5. PMC: 3683728. DOI: 10.1073/pnas.1305172110. View

13.

Hsu C, Peng K, Kang M, Chen Y, Yang Y, Tsai C . TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012; 2(3):568-79. DOI: 10.1016/j.celrep.2012.08.030. View

14.

Chou J, Lin J, Brenot A, Kim J, Provot S, Werb Z . GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013; 15(2):201-13. PMC: 3660859. DOI: 10.1038/ncb2672. View

15.

Ota D, Mimori K, Yokobori T, Iwatsuki M, Kataoka A, Masuda N . Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol. 2011; 38(4):955-62. DOI: 10.3892/ijo.2011.926. View

16.

Ibrahem L, Mahfouz R, Elhelw L, Abdsalam E, Soliman R . Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis. 2014; 54(1):84-9. DOI: 10.1016/j.bcmd.2014.07.015. View

17.

Yang T, Liang Y, Lin Q, Liu J, Luo F, Li X . miR-29 mediates TGFβ1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts. J Cell Biochem. 2012; 114(6):1336-42. DOI: 10.1002/jcb.24474. View

18.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

19.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

20.

Song S, Poliseno L, Song M, Ala U, Webster K, Ng C . MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 2013; 154(2):311-324. PMC: 3767157. DOI: 10.1016/j.cell.2013.06.026. View